Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2011-08-30
2011-08-30
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C435S069100, C435S069700
Reexamination Certificate
active
08007781
ABSTRACT:
This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo.
REFERENCES:
patent: 4898730 (1990-02-01), Levy et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5426097 (1995-06-01), Stern et al.
patent: 5547846 (1996-08-01), Bartsch et al.
patent: 5582831 (1996-12-01), Shinitzky
patent: 5591716 (1997-01-01), Siebert et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5629161 (1997-05-01), Muller et al.
patent: 5674486 (1997-10-01), Sobol et al.
patent: 5744133 (1998-04-01), Lathe et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5821088 (1998-10-01), Darzins et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5834309 (1998-11-01), Thompson et al.
patent: 5837251 (1998-11-01), Srivastava
patent: 5844089 (1998-12-01), Hoffman et al.
patent: 5854202 (1998-12-01), Dedhar
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5951975 (1999-09-01), Falo, Jr. et al.
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5997869 (1999-12-01), Goletz et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6013262 (2000-01-01), Frazer et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6017735 (2000-01-01), O'Hare et al.
patent: 6020309 (2000-02-01), Campo et al.
patent: 6030618 (2000-02-01), Srivastava
patent: 6046158 (2000-04-01), Ariizumi et al.
patent: 6066716 (2000-05-01), Wallen et al.
patent: 6235523 (2001-05-01), Gajewczyk et al.
patent: 6331388 (2001-12-01), Malkovsky et al.
patent: 6399070 (2002-06-01), Srivastava et al.
patent: 6403080 (2002-06-01), Segal
patent: 6410027 (2002-06-01), Srivastava
patent: 6410028 (2002-06-01), Srivastava
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6734173 (2004-05-01), Wu et al.
patent: 7001995 (2006-02-01), Neeper et al.
patent: 7318928 (2008-01-01), Wu et al.
patent: 7342002 (2008-03-01), Wu et al.
patent: 2001/0034042 (2001-10-01), Srivastava
patent: 2002/0064771 (2002-05-01), Zhong et al.
patent: 2002/0091246 (2002-07-01), Pardoll et al.
patent: 2002/0182586 (2002-12-01), Morris et al.
patent: 2004/0028693 (2004-02-01), Wu et al.
patent: 2004/0086845 (2004-05-01), Wu et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0048467 (2005-03-01), Sastry et al.
patent: 2005/0054820 (2005-03-01), Wu et al.
patent: 2005/0277605 (2005-12-01), Wu et al.
patent: 2007/0026076 (2007-02-01), Wu et al.
patent: 2413543 (2002-01-01), None
patent: 0 763 740 (1997-03-01), None
patent: WO-89/12455 (1989-12-01), None
patent: WO-92/05248 (1992-04-01), None
patent: WO-93/20844 (1993-10-01), None
patent: WO-94/04696 (1994-03-01), None
patent: WO-94/29459 (1994-12-01), None
patent: WO-95/17212 (1995-06-01), None
patent: WO-96/36643 (1996-11-01), None
patent: WO-97/03703 (1997-02-01), None
patent: WO-97/06685 (1997-02-01), None
patent: WO-97/41440 (1997-11-01), None
patent: WO-98/23735 (1998-06-01), None
patent: WO-98/32866 (1998-07-01), None
patent: WO-98/48003 (1998-10-01), None
patent: WO-99/07860 (1999-02-01), None
patent: WO-99/42472 (1999-08-01), None
patent: WO-99/58658 (1999-11-01), None
patent: WO 99/07869 (1999-12-01), None
patent: WO-99/65940 (1999-12-01), None
patent: WO-01/29233 (2001-04-01), None
patent: WO-02/09645 (2002-02-01), None
patent: WO-02/12281 (2002-02-01), None
patent: WO-02/061113 (2002-08-01), None
patent: WO-02/074920 (2002-09-01), None
patent: WO-03/008543 (2003-01-01), None
patent: WO-03/083052 (2003-10-01), None
patent: WO-03/085085 (2003-10-01), None
patent: WO-2004/030636 (2004-04-01), None
patent: WO-2004/060304 (2004-07-01), None
patent: WO-2004/098526 (2004-11-01), None
patent: WO-2005/047501 (2005-05-01), None
patent: WO-2005/081716 (2005-09-01), None
patent: WO-2006/073970 (2006-07-01), None
patent: WO-2006/081323 (2006-08-01), None
Aguiar et al., “Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device,” Vaccine, 20:275-280 (2001).
Alexander et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides,” Immunity, 1:751-761 (1994).
Anonymous: “E7 vaccine (NSC 723254),” Timeless Success Story, Online, XP002394109 (2002).
Anthony et al., “Priming of CD8 CTL Effector Cells in Mice by Immunizationwith a Stress-Protein-Influenza Virus Nucleoprotein Fusion Molecule,” Vaccine, 17(4):373-383 (1999).
Asea et al., “Novel Signal Transduction Pathway Utilized by Extracellular HSP70,” Journal of Biological Chemistry, 277(7)15028-15034 (2002).
Ausbel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, 1989.
Babiuk et al., “Immunization of animals: from DNA to the dinner plate,” Veterinary Immunology and Immunopathology, 72:189-202 (1999).
Bae et al., “Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Casual Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy,” Clin. Cancer Res., 13(1):341-349 (2007).
Banchereau, J., “Dendritic Cells: Therapeutic Potentials,” Transfus Sci 18(2):313-326 (1997).
Banu et al., “Modulation of Haematopoietic Progenitor Development by FLT-3 Ligand,”Cylokine, 11(9):679-688 (1999).
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol., 22:1365-1372 (1992).
Becker et al., “CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes,” Journal of Cell Biology, 158(7):1277-1285 (2002).
Beissbarth et al., “Increased efficiency of folding and peptide loading of mutant MHC class I molecules,” Eur. J. Immunol., 30:1203-1213 (2000).
Benton et al., “DNA Vaccine Strategies for the Treatment of Cancer,” Curr Top Microbiol Immunol., 226:1-20 (1998).
Bhoola et al., “Diagnosis and management of epithelial ovarian cancer,” Obstet. Gynecol., 107(6):1399-1410 (2006).
Biragyn et al., “Genetic fusion of chemokines to a self tumor antigen induces protective, T-Cell dependent antitumor immunity,” Nature Biotechnology, 17:253-258 (1993) Abstract.
Blachere et al., “Heat shock Protein-peptide complexes, Reconstituted in vitro, Elicit Peptide-specific cytotoxic T Lymphocyte Response and Tumor Immunity,” J. Exp. Med., 186(8)1315-1322 (1997).
Blachere et al. “Heat shock proteins against cancer,” J. of Immunotherapy Emphasis Tumor Immunol., 14:352-356 (1993).
Bohm et al., “Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses,” Vaccine, 16:949-954 (1998).
Boyle et al, “Enhanced responses to a DNA vaccine encoding a fusion antigen that directed to sites of immune induction,” Nature, 392:408-411 (1998).
Bredenbeek et al., “Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs,” Journal of Virology, 67(11):6439-6446 (1993).
Breitburd et al., “Human papillomavirus vaccines,” Cancer Biology, 9:431-445 (1999).
Brossart et al., “Identification of HLA-A2-Restricte
Hung Chien-Fu
Wu Tzyy-Choou
Foley & Hoag LLP
Li Q. Janice
The Johns Hopkins University
LandOfFree
Molecular vaccine linking an endoplasmic reticulum chaperone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular vaccine linking an endoplasmic reticulum chaperone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular vaccine linking an endoplasmic reticulum chaperone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2755151